Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2

  • Santiago, Llipsy
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • González-Ramírez, Andrés M.
  • Macías-León, Javier
  • Moreo, Eduardo
  • Redrado, Sergio
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Aguilo, Nacho
  • del Mar Encabo-Berzosa, Maria
  • Hidalgo, Sandra
  • Galvez, Eva M.
  • Ramirez-Labrada, Ariel
  • de Miguel, Diego
  • Benito, Rafael
  • Miranda, Patricia
  • Fernández, Antonio
  • Domingo, José M.
  • Serrano, Laura
  • Yuste, Cristina
  • Villanueva-Saz, Sergio
  • Paño-Pardo, José R.
  • Pardo, Julián
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Sars-cov-2 seroprevalence in household domestic ferrets (Mustela putorius furo)

  • Giner, Jacobo
  • Villanueva-Saz, Sergio
  • Tobajas, Ana Pilar
  • Pérez, María Dolores
  • González, Ana
  • Verde, Maite
  • Yzuel, Andrés
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Pardo, Julián
  • Santiago, Llipsy
  • Paño, José Ramón
  • Ruíz, Héctor
  • Lacasta, Delia
  • Fernández, Antonio
Animal infections with SARS-CoV-2 have been reported in different countries and several animal species have been proven to be susceptible to infection with SARS-CoV-2 both naturally and by experimental infection. Moreover, infections under natural conditions in more than 20 mink farms have been reported where humans could have been the source of infection for minks. However, little information is available about the susceptibility of pet animals under natural conditions and currently there is no SARS-CoV-2 epidemiological assessment occurrence in household ferrets. In this study, the presence of SARS-CoV-2 antibodies was evaluated in serum samples obtained from 127 household ferrets (Mustela putorius furo) in the Province of Valencia (Spain). Two ferrets tested positive to SARS-CoV-2 (1.57%) by in-house enzyme-linked immunosorbent assay based on receptor binding domain (RBD) of Spike antigen. Furthermore, anti- RBD SARS-CoV-2 antibodies persisted at detectable levels in a seropositive SARS-CoV-2 domestic ferret beyond 129 days since the first time antibodies were detected. This study reports for the first time the evidence of household pet ferrets exposure to SARS-CoV-2 in Spain to date.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study

  • Irún, Pilar
  • Gracia, Rafael
  • Piazuelo, Elena
  • Pardo, Julián
  • Morte, Elena
  • Paño, José Ramon
  • Boza, Julio
  • Carrera-Lasfuentes, Patricia
  • Higuera, Gustavo A.
  • Lanas, Ángel
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC–MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E2. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality

  • Albert, Marie-Christine
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • De Miguel, Diego
  • Peña, Natacha
  • Montinaro, Antonella
  • Varanda, Ana Beatriz
  • Theobald, Sebastian J.
  • Areso, Itziar
  • Saggau, Julia
  • Koch, Manuel
  • Liccardi, Gianmaria
  • Peltzer, Nieves
  • Rybniker, Jan
  • Hurtado-Guerrero, Ramón
  • Merino, Pedro
  • Monzón, Marta
  • Badiola, Juan J.
  • Reindl-Schwaighofer, Roman
  • Sanz-Pamplona, Rebeca
  • Cebollada-Solanas, Alberto
  • Megyesfalvi, Zsolt
  • Dome, Balazs
  • Secrier, Maria
  • Hartmann, Boris
  • Bergmann, Michael
  • Pardo, Julián
  • Walczak, Henning
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

  • Mata, Elena
  • Broset, Esther
  • Matute, Carlos
  • Stoian, Andrei
  • Adame, Susana
  • Alejo, Teresa
  • López, Alexandre
  • Andrés, Beatriz
  • Heredero, Juan
  • de Miguel, Diego
  • Giménez-Warren, Javier
  • Lampaya, Verónica
  • Casabona, Diego
  • Calvo, Alba
  • Quincoces, Gema
  • Peñuelas, Iván
  • Gamazo, Carlos
  • Uranga, Iratxe
  • Peña, Natacha
  • Arias, Maykel
  • Pardo, Julián
  • Moreno, Bernardino
  • Badiola, Juan
  • Martínez-Oliván, Juan
  • Pérez-Herrán, Esther
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.